Comprehensive Income (Loss), Net of Tax, Attributable to Parent of Acrivon Therapeutics, Inc. from 30 Sep 2022 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
Summary
Acrivon Therapeutics, Inc. quarterly and annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent in USD history and change rate from 30 Sep 2022 to 30 Sep 2025.
  • Acrivon Therapeutics, Inc. Comprehensive Income (Loss), Net of Tax, Attributable to Parent for the quarter ending 30 Sep 2025 was $18,228,000, a 16% increase year-over-year.
  • Acrivon Therapeutics, Inc. Comprehensive Income (Loss), Net of Tax, Attributable to Parent for the twelve months ending 30 Sep 2025 was $82,421,000, a 8.6% decline year-over-year.
  • Acrivon Therapeutics, Inc. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2024 was $80,026,000, a 33% decline from 2023.
  • Acrivon Therapeutics, Inc. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2023 was $60,376,000, a 93% decline from 2022.
Source SEC data
View on sec.gov
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Trailing 12 Months (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Quarterly (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, YoY Quarterly Change (%)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Annual (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, YoY Annual Change (%)

Acrivon Therapeutics, Inc. Quarterly Comprehensive Income (Loss), Net of Tax, Attributable to Parent (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $82,421,000 $18,228,000 +$3,412,000 +16% 01 Jul 2025 30 Sep 2025 10-Q 13 Nov 2025 2025 Q3
Q2 2025 $85,833,000 $21,183,000 -$2,436,000 -13% 01 Apr 2025 30 Jun 2025 10-Q 13 Aug 2025 2025 Q2
Q1 2025 $83,397,000 $19,844,000 -$3,371,000 -20% 01 Jan 2025 31 Mar 2025 10-Q 14 May 2025 2025 Q1
Q4 2024 $80,026,000 $23,166,000 -$4,133,000 -22% 01 Oct 2024 31 Dec 2024 10-K 27 Mar 2025 2024 FY
Q3 2024 $75,893,000 $21,640,000 -$7,299,000 -51% 01 Jul 2024 30 Sep 2024 10-Q 13 Nov 2025 2025 Q3
Q2 2024 $68,594,000 $18,747,000 -$4,397,000 -31% 01 Apr 2024 30 Jun 2024 10-Q 13 Aug 2025 2025 Q2
Q1 2024 $64,197,000 $16,473,000 -$3,821,000 -30% 01 Jan 2024 31 Mar 2024 10-Q 14 May 2025 2025 Q1
Q4 2023 $60,376,000 $19,033,000 01 Oct 2023 31 Dec 2023 10-K 27 Mar 2025 2024 FY
Q3 2023 $14,341,000 -$5,010,000 -54% 01 Jul 2023 30 Sep 2023 10-Q 13 Nov 2024 2024 Q3
Q2 2023 $14,350,000 01 Apr 2023 30 Jun 2023 10-Q 13 Aug 2024 2024 Q2
Q1 2023 $12,652,000 01 Jan 2023 31 Mar 2023 10-Q 14 May 2024 2024 Q1
Q3 2022 $9,331,000 01 Jul 2022 30 Sep 2022 10-Q 09 Nov 2023 2023 Q3

Acrivon Therapeutics, Inc. Annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $80,026,000 -$19,650,000 -33% 01 Jan 2024 31 Dec 2024 10-K 27 Mar 2025 2024 FY
2023 $60,376,000 -$29,114,000 -93% 01 Jan 2023 31 Dec 2023 10-K 27 Mar 2025 2024 FY
2022 $31,262,000 01 Jan 2022 31 Dec 2022 10-K 28 Mar 2024 2023 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.